NCT07925554
Interferon-α Maintenance in Favorable-Risk AML
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
2-Year Cumulative Incidence of Relapse
Timeframe: 2 years after enrollment
Secondary (4)
2-Year Event-Free Survival (EFS)
2-Year Overall Survival (OS)
MRD Conversion Rate Among Patients With MRD-Positive Disease at Enrollment
Number of Participants With Grade 3 or Higher Adverse Events
Arms and interventions
Peginterferon Alfa-2b Maintenance TherapyExperimental
Eligible patients with favorable-risk acute myeloid leukemia (AML) in first complete remission (CR1) after consolidation chemotherapy will receive peginterferon alfa-2b injection at a dose of 135 μg once weekly by subcutaneous injection for 6 months. Participants will be monitored for disease relapse, measurable residual disease (MRD), survival, and treatment-related adverse events, with follow-up for 2 years after enrollment.
Biologicals: pegylated interferon alfa-2b
Sites
1 site in 1 country
- Peking University People's HospitalBeijing, China